TY - JOUR KW - Antibodies, Bacterial KW - Antigens, Bacterial KW - Dapsone KW - Drug Therapy, Combination KW - Glycolipids KW - Humans KW - leprosy KW - Mycobacterium leprae AU - Chanteau S AU - Cartel J L AU - Celerier P AU - Plichart R AU - Desforges S AU - Roux J AB -
Multibacillary (MB) and paucibacillary (PB) leprosy patients were tested for circulating phenolic glycolipid-I (PGL-I) antigen and antibodies before treatment. In the 27 MB patients tested, 27 (100%) were antigen positive with levels ranging from 50 to 5000 ng/ml, and 26 (96%) were antibody positive with titers ranging from 1000 to 64,000. Although the antigen and antibody levels were much higher in MB than in PB patients, we could not demonstrate a correlation between the number of acid-fast bacilli/mg of skin biopsy and these two parameters in 14 MB patients. After starting daily multidrug therapy, 10 MB patients were monitored monthly. As much as 88.75% +/- 10.8% of the PGL-I antigen was cleared from the bloodstream after 1 month while the anti-PGL-I antibody remained stable. This rapid decrease in the PGL-I antigen level strongly suggests the usefulness of this test for monitoring MB patients under chemotherapy.
BT - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association C1 -http://www.ncbi.nlm.nih.gov/pubmed/2681456?dopt=Abstract
DA - 1989 Dec IS - 4 J2 - Int. J. Lepr. Other Mycobact. Dis. LA - eng N2 -Multibacillary (MB) and paucibacillary (PB) leprosy patients were tested for circulating phenolic glycolipid-I (PGL-I) antigen and antibodies before treatment. In the 27 MB patients tested, 27 (100%) were antigen positive with levels ranging from 50 to 5000 ng/ml, and 26 (96%) were antibody positive with titers ranging from 1000 to 64,000. Although the antigen and antibody levels were much higher in MB than in PB patients, we could not demonstrate a correlation between the number of acid-fast bacilli/mg of skin biopsy and these two parameters in 14 MB patients. After starting daily multidrug therapy, 10 MB patients were monitored monthly. As much as 88.75% +/- 10.8% of the PGL-I antigen was cleared from the bloodstream after 1 month while the anti-PGL-I antibody remained stable. This rapid decrease in the PGL-I antigen level strongly suggests the usefulness of this test for monitoring MB patients under chemotherapy.
PY - 1989 SP - 735 EP - 43 T2 - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association TI - PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. UR - http://ila.ilsl.br/pdfs/v57n4a01.pdf VL - 57 SN - 0148-916X ER -